IgA is the predominant isotype of anti- β 2 glycoprotein I in patients with COVID-19
Laboratory Medicine · 2024
DOI: 10.1093/labmed/lmad097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, 2024. Verfasst von Sarra Melayah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology, Farhat Hached University Hospital, Sousse, Tunisia. Hauptthemen laut MEDLINE: COVID-19, Immunoglobulin A, beta 2-Glycoprotein I, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Objective
The aim of this research was to determine the frequency of antiphospholipid antibodies (aPL) in patients with COVID-19.
Methods
The frequency and titers of anticardiolipin antibodies (aCL) and anti-β2 glycoprotein I antibodies (aβ2GPI) were determined in sera of adult patients hospitalized with COVID-19. Immunoglobulin (Ig)G, IgA, IgM aCL, and aβ2GPI were measured using enzyme-linked immunosorbent assay.
Results
Eighty-three patients were included in the study. The mean age of patients was 62 ± 13.9 years, ranging from 23 to 86 years. Stratification according to severity of infection divided patients in 2 groups: 45 patients with moderate infection and 38 patients with critical or severe infection. Out of the 83 patients suffering from COVID-19, aPL (aCL or aβ2GPI) were detected in 24 patients (28.9%). IgG, IgA and IgM aβ2GPI were positive in 2.4%, 16.9% and 8.4%, respectively. IgG, IgA and IgM aCL showed positivity in 7.2%, 0%, and 4.8%, respectively. The frequency of aPL was 36.8% in patients with critical/severe infection and 22.2% in patients with moderate infection. In critical/severe patients, the frequency of aβ2GPI was significantly higher than aCL (34.2% vs 13.2%, P = .03) and aβ2GPI-IgA were significantly more frequent than aβ2GPI-IgG (21.1% vs 2.6%, P = .028).
Conclusion
In this cross-sectional study, aPL and particularly aβ2GPI-IgA were common in patients with COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunology, Farhat Hached University Hospital, Sousse, Tunisia.
- Department of Immunology, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.
- LR12SP11, Department of Biochemistry, Sahloul University Hospital, Sousse, Tunisia.
- Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia.
- LR14SP02, Research Unit "Epidemiology and Immunogenetics of Viral Infections," Sahloul University Hospital, Sousse, Tunisia.
- Laboratory of Biochemistry, Farhat Hached University Hospital, Sousse, Tunisia.
ORCID-Profile: Sarra Melayah, Mariam Ghozzi, Amani Mankaï
Zitieren
APA
Melayah, S., Omrani, N., Alouini, H., Ghozzi, M., Mrad, S., Boussarsar, M., Chaouch, H., Hachfi, W., Letaief, A., Mankaï, A., & Ghedira, I. (2024). IgA is the predominant isotype of anti- β 2 glycoprotein I in patients with COVID-19. Laboratory Medicine. https://doi.org/10.1093/labmed/lmad097
Vancouver
Melayah S, Omrani N, Alouini H, Ghozzi M, Mrad S, Boussarsar M, et al. IgA is the predominant isotype of anti- β 2 glycoprotein I in patients with COVID-19. Laboratory Medicine. 2024. doi:10.1093/labmed/lmad097
BibTeX
@article{Melayah2024,
author = {Melayah, Sarra and Omrani, Nouha and Alouini, Hela and Ghozzi, Mariam and Mrad, Sawssen and Boussarsar, Mohamed and Chaouch, Houda and Hachfi, Wissem and Letaief, Amel and Mankaï, Amani and Ghedira, Ibtissem},
title = {IgA is the predominant isotype of anti- β 2 glycoprotein I in patients with COVID-19},
journal = {Laboratory Medicine},
year = {2024},
doi = {10.1093/labmed/lmad097}
}
EUVIMED